Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
animal early embryo extract
- Development stage
- Phase 1
- Lead developer
- Anhui HygeianCells BioMedical
- Administration
- Intraarticular
01
Overview
Animal early embryo extract (designated ceAF) is a cell-free biologic preparation derived from early chick embryo amniotic fluid. It contains native growth-promoting factors and inflammatory factor inhibitors. Unlike direct embryonic stem cell therapies, ceAF is cell-free, which avoids tumorigenic risks and sourcing limitations while retaining biological activity. Developed by HygeianCells BioMedical, ceAF is being evaluated in clinical trials for the treatment of knee osteoarthritis via intra-articular injection. Preclinical studies have also demonstrated its potential in wound healing by promoting M2 macrophage polarization and transient senescence.
- Other names
- chick early amniotic fluidchick early embryo amniotic fluidchick early embryo extract
Beyond the preview
Go deeper on animal early embryo extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on animal early embryo extract.